Viewing data from:

EPOPROSTENOL SODIUM

ANDA

EPOPROSTENOL SODIUM | A213913 | MYLAN PHARMACEUTICALS INC

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: VELETRI(TE code: AP2)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. 1:2020cv00110 2 patentsANDA 213913epoprostenol sodium	WVND	2020-06-09	Terminated 2024-03-18	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

API Supply Chain4 active DMFs2 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

PHARMACIA AND UPJOHN SUB PFIZER INCEPOPROSTENOL SODIUM (U-53,217A)

DMF 60651985

CAYMAN PHARMA SROEPOPROSTENOL SODIUM

DMF 215842008

MSN LABORATORIES PRIVATE LTDEPOPROSTENOL SODIUM [ROUTE CODE - ED]

DMF 274202013

SUN PHARMACEUTICAL INDUSTRIES LTDEPOPROSTENOL SODIUM

DMF 302632017

JOHNSON MATTHEY PHARMA SERVICESInactiveEPOPROSTENOL SODIUM

DMF 180192005

EVERLIGHT CHEMICAL INDUSTRIAL CORPInactiveEPOPROSTENOL SODIUM

DMF 213112008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 0.5MG BASE/VIAL

AP2

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Jun 12, 2024

No patent or exclusivity listings for this strength.

#002 — EQ 1.5MG BASE/VIAL

AP2

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Jun 12, 2024